MedTrace Logo

N-acetylcysteine Effects on Tetrahydrocannabinol

NCT02335060 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-01-31

No results posted yet for this study

Summary

The overall purpose of this study is to examine the effect of N-acetylcysteine (NAC) on the acute effects of Delta-9-tetrahydrocannabinol (THC). This will be tested by pretreating healthy individuals with NAC and then assessing their responses to THC.

Conditions

  • Healthy

Interventions

DRUG

Delta-9-THC

Active Delta-9-THC (0.036mg/Kg) given intravenously.

DRUG

N-acetylcysteine

A pill given orally.

DRUG

Placebo

Placebo (about a quarter spoon of alcohol with no THC) given intravenously.

DRUG

Placebo

Placebo "sugar" pill given orally with no N-acetylcysteine.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Mohini Ranganathan, MD · Yale University Medical School

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-02
Primary Completion
2014-09-16
Completion
2014-09-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02335060 on ClinicalTrials.gov